IBM owns 4,388 quantum computing patent families, far ahead of Google, Microsoft and D-Wave. The full 2026 ownership ranking and what the concentration means.
FRAND Royalty Rate: How Courts Actually Price a SEP Licence
How a FRAND royalty rate is actually set — comparable licences, the top-down method, and the per-device rates courts have put on the record.
CAR-T Patent Landscape 2026: What Developers Must Know
The 2026 CAR-T patent landscape mapped: the foundational CD19, 4-1BB and CD28 patents, who controls them, and how Juno v. Kite reshaped what is enforceable.
Freedom to Operate vs Patentability: What’s the Difference?
Patentability asks whether your invention is new. Freedom to operate asks whether you can sell it without infringing. Here is how the two searches differ and why a product launch needs both.
Freedom to Operate in Semiconductors: How to Clear a Chip Before Tape-Out
A practical guide to freedom to operate in semiconductors: what it clears, why the patent thicket makes it hard, the five-step method, and design-around vs licence.
Who Owns Humanoid Robot Patents? The Complete 2026 List
The companies, countries and universities that own the most humanoid robot patents in 2026 — and what the ownership map means for anyone filing in the field.
Generative AI Patents: Who’s Filing and Who Leads in 2026
Generative AI patent families more than tripled in two years. Here is who is filing, who leads by country and company, and what the surge means for your IP strategy.
Cybersecurity Patents 2026: The Definitive Guide to Filing Trends
A data-driven look at cybersecurity patents 2026: the clusters that are compounding, the owners that dominate, and how to read the filing trends.
Green Hydrogen Patents: What EPO–IEA Filing Data Reveals
Green hydrogen patents surged from 2011 to 2020 as electrolysis overtook fossil routes. See who leads, who is falling behind, and what the filing data signals.
Freedom to Operate for Medical Devices: A Clearance Guide
Why freedom to operate for medical devices is a separate gate from FDA clearance — and how to clear a device for the US and EU before launch.
Semaglutide Patent Expiration: 4 Essential Cliff Dates by Market
Semaglutide’s patent cliff lands in 2026 in Canada, India and Brazil but not until roughly 2032 in the US. Here is the country-by-country timeline and what it means.
Post-Quantum Cryptography Patents: What They Cover and Who Owns Them
A plain-English guide to post-quantum cryptography patents: what is patentable when the algorithm is standardized, who owns ML-KEM, and why the deadlines matter.
Who Owns Semiconductor Patents? Top Chip Holders in 2026
Samsung, TSMC, Qualcomm, IBM and Huawei dominate the semiconductor patent record — but grant counts, PCT filings and standard-essential portfolios tell different stories. The 2026 ranking, by company and by office.
Patent Portfolio Valuation in Acquisitions: A Buyer’s Playbook
How buyers actually price a patent portfolio inside an acquisition — the three valuation approaches, purchase-price allocation, and how diligence findings move the number.
AI Patent Filing Trends in 2026: What the WIPO and USPTO Data Show
The data behind AI patent filing trends in 2026 — how fast GenAI patenting is growing, who is filing, where the filings originate, and what it means for your strategy.
Patent Risks in Semiconductor M&A: 6 Due-Diligence Checks
In semiconductor deals the patent estate is the asset. Here is the due-diligence checklist that separates a clean portfolio from an expensive surprise.
Collaborative Robot Patents: Inside the Cobot Landscape
A practical map of the collaborative robot patent landscape in 2026 — who owns it, which cobot technologies are most densely fenced, and how to clear a launch.
Solid-State Battery Patents: Who Is Winning the Race
A data-driven look at solid-state battery patents — who leads, why the published counts disagree, and what the filing curve signals about timing.
Quantum Computing Market Size: The 2030 Forecast, and the Reality Behind It
The quantum computing market size is heading for $20.2 billion by 2030 on some forecasts, while 2025 revenue was near $1 billion. We separate the served market from the trillion-dollar hype and show what patent data adds.
Biotech Patent Due Diligence: 7 Checks Before a Deal
In a biotech deal you are not buying today’s revenue — you are buying the years of exclusivity behind it. Biotech patent due diligence is how you find out how many years that really is, before you sign.